BioVie is a clinical-stage company developing drug therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, Co.'s orphan drug candidate, BIV201 (continuous infusion terlipressin), is being developed as a future treatment option for patients suffering from ascites and other life-threatening complications of liver cirrhosis caused by nonalcoholic steatohepatitis, hepatitis, and alcoholism. In neurodegenerative disease, Co.'s product candidate, NE3107, is an orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and primary pathological inflammatory cascades with a mechanism of action. We show 15 historical shares outstanding datapoints in our BIVI shares outstanding history coverage, used to compute BIVI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BIVI market cap history over the course of time is important for investors
interested in comparing BIVI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BIVI versus a peer is one thing; comparing
BIVI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BIVI can fluctuate over the course of history.
With this page we aim to empower investors researching BIVI by allowing them to research the BIVI market cap history. |
Free BIVI Email Alerts:
Video: The Importance of Market Cap
